I am an Associate Attending Geneticist in the Clinical Genetics Service in the Department of Medicine and Associate Director of Bioinformatics of the Robert and Kate Niehaus Center for Inherited Cancer Genomics at MSK. I hold a secondary appointment as Associate Professor of Genetics Research in Medicine at the Weill Cornell Medical College, New York, NY.
My research focuses on the following areas:
- Inherited cancer susceptibility: Identifying and characterizing novel germline genomic alterations associated with cancer risk.
- Integrative germline–somatic genomics: Investigating the interplay between inherited and acquired genomic alterations using large-scale clinical and real-world population data.
- Precision oncology: Integrating germline and somatic genomic variation to inform patient stratification and targeted therapeutic strategies.
I lead the Inherited Lung Cancer Genomics Initiative, which investigates the contributions of inherited and somatic alterations in DNA damage repair pathways to lung cancer susceptibility and their interactions with environmental risk factors. My team develops statistical, computational, and AI/machine learning pipelines to support translational research and clinical oncology.
I also co-lead hereditary cancer genetics projects in collaboration with MSK clinicians, spanning multiple cancer types, including renal, colorectal, prostate, and breast cancers. These collaborations involve study design, genomic data analysis, and the translation of findings into clinical insights, with a particular emphasis on understanding the contribution of inherited pathogenic and likely pathogenic variants to cancer susceptibility.
My research is supported by an NCI R37 MERIT Award as Principal Investigator, collaborative NCI R01 funding as a Co-Investigator, and funding from the Niehaus Center and other research partners.
Carlo MI, Schroeder A, Liu J, Ravichandran V, Mehta N, Kemel Y, Zong G, Liu Y, Latham A, Shah N, Feldman D, Voss MH, Kotecha R, Stadler ZK, Robson ME, Mehine M, Bandlamudi C, Berger MF, Chen Y, Mandelker D, Bolton K, Mukherjee S, Offit K, Motzer R.Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management. J Natl Cancer Inst. 2026 Aug 24:djag290. doi: 10.1093/jnci/djag290. Online ahead of print.PMID: 42635527
Mukherjee S*, Bandlamudi C, Hellmann MD, Kemel Y, Drill E, Rizvi H, Tkachuk K, Khurram A, Walsh MF, Zauderer MG, Mandelker D, Topka S, Zehir A, Srinivasan P, Esai Selvan M, Carlo MI, Cadoo KA, Latham A, Hamilton JG, Liu YL, Lipkin SM, Belhadj S, Bond GL, Gümüş ZH, Klein RJ, Ladanyi M, Solit DB, Robson ME, Jones DR, Kris MG, Vijai J, Stadler ZK, Amos CI, Taylor BS, Berger MF, Rudin CM, Offit K. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. (Cancer Epidemiol Biomarkers Prev. 2022 Apr 27: cebp.EPI-21-1287-A.2021. doi: 10.1158/1055-9965.EPI-21-1287. Epub ahead of print. PMID: 35477182
Natasha Rekhtman, Sam E Tischfield, Christopher A Febres-Aldana, Jake J Lee, Jason C Chang, Benjamin O Herzberg, Pier Selenica, Hyung Jun Woo, Chad Vanderbilt, Soo-Ryum Yang, Fei Xu, Anita S Bowman, Edaise M da Silva, Anne Marie Noronha, Diana Mandelker, Miika Mehine, Semanti Mukherjee, Juan Blanco-Heredia, John J Orgera, Gouri J Nanjangud, Marina K Baine, Jennifer L Sauter, William D Travis, Omid Savari,Andre L Moreira, Christina J Falcon, Francis M Bodd, Christina E Wilson, Jacklynn V Sienty, Parvathy Manoj, Harsha Sridhar, Lu Wang, Noura J Choudhury, Michael Offin, Helena A Yu, Alvaro Quintanal-Villalonga, Michael F Berger, Marc Ladanyi, Mark T A Donoghue, Jorge S Reis-Filho, Charles M Rudin Chromothripsis-mediated small cell lung carcinoma (Cancer Discovery. 2025 Jan 13;15(1):83-104. doi: 10.1158/2159-8290.CD-24-0286.PMID: 39185963)
Brent Mabey, Elisha Hughes, Matthew Kucera, Timothy Simmons, Brooke Hullinger, Holly J Pederson, Lamis Yehia, Charis Eng, Judy Garber, Monique Gary, Ora Gordon, Jennifer R Klemp, Semanti Mukherjee, Joseph Vijai, Kenneth Offit, Olufunmilayo I Olopade, Sandhya Pruthi, Allison Kurian, Mark E Robson, Pat W Whitworth, Tuya Pal, Sarah Ratzel, Susanne Wagner, Jerry S Lanchbury, Katherine Johansen Taber, Thomas P Slavin, Alexander Gutin, Longitudinal validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. (Genet Med. 2024 May 28:101128. doi: 10.1016/j.gim.2024.101128. Online ahead of print. PMID: 38829299)
Tian R, Wiley B, Liu J, Zong X, Truong B, Zhao S, Uddin MM, Niroula A, Miller CA, Mukherjee S, Heiden BT, Luo J, Puri V, Kozower BD, Walter MJ, Ding L, Link DC, Amos CI, Ebert BL, Govindan R, Natarajan P, Bolton KL, Cao Y. Clonal Hematopoiesis and Risk of Incident Lung Cancer. (J Clin Oncol. 2023 Mar 1;41(7):1423-1433. doi: 10.1200/JCO.22.00857. PMID: 36480766
Ji X, Mukherjee S*, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, Xiao X, Han Y, Gorlova O, Hung RJ, Brhane Y, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Byun J, Dragnev KH, Field JK, Kiemeney LF, Lazarus P, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Diao N, Su L, Song L, Zhang R, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez- Tardon G, Heijden EHFMV, Kim JH, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Goodman GE, Cox A, Taylor F, Woll P, Wichmann E, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Butler LM, Offit K, Srinivasan P, Bandlamudi C, Hellmann MD, Solit DB, Robson ME, Rudin CM, Stadler ZK, Taylor BS, Berger MF, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Artigas MS, Shete S, Brenner H, Chanock S, Brennan P, McKay JD, Amos CI. Protein-altering germline mutations implicate novel genes related to lung cancer development. (Nat Commun. 2020 May 11;11(1):2220. doi: 10.1038/s41467-020-15905-6. PMID: 32393777; PMCID: PMC7214407
Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S*. Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. (J Clin Oncol. 2020 May 1;38(13):1398-1408. doi: 10.1200/JCO.19.02010. Epub 2020 Jan 10. PMID: 31922925; PMCID: PMC7193752
View a full listing of Semanti Mukherjee’s journal articles.
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Semanti Mukherjee discloses the following relationships and financial interests:
-
Regeneron Pharmaceuticals, Inc.
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures